Low-dose chemo combo for advanced colorectal cancer
Part of Cancer, Digestive system clinical trials.
This trial tests a lower dose of a chemotherapy pill (trifluridine/tipiracil) combined with bevacizumab for advanced colorectal cancer that has not responded to at least two prior treatments. The goal is to see if this combination can help control the cancer with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years old or older.
- You have been diagnosed with colon or rectal cancer that has spread or cannot be removed by surgery.
- You have already tried two or more types of chemotherapy, or you could not tolerate the last one.
- You are well enough to be up and about (able to do daily activities) and expected to live at least 3 more months.
- Your blood cell counts and liver/kidney function are within safe limits as checked by your doctor.
- You agree to follow the study plan and sign a consent form.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests adding a new drug combo (TAS-102 and bevacizumab) to standard second-line treatment for advanced colorectal cancer, followed by local treatments. It may help if your first treatment stopped working and you are otherwise in good health.
This trial tests a combination of two drugs—bevacizumab and trifluridine/tipiracil—given together to see if it lowers the risk of a serious drop in white blood cells (neutropenia) in people with advanced colorectal cancer. The goal is to make treatment safer and more tolerable.
This trial tests a new combination of drugs (liposomal irinotecan, 5-FU/LV, and bevacizumab) for people with advanced colorectal cancer that cannot be removed by surgery. The goal is to see if this treatment is safe and effective in shrinking tumors and improving outcomes.
This trial tests a new combination of drugs (trifluridine/tipiracil, bevacizumab, and serplulimab) for people with colorectal cancer that has spread to the belly and has already had surgery. The goal is to see if this treatment can help control the cancer and improve survival.
This trial tests a new drug combination for colorectal cancer that has not responded to other treatments. It compares the new drug with a standard treatment to see which is more effective.
This Phase 2 study tests a treatment plan that alternates two cancer pills and adds bevacizumab (a blood-vessel drug) for metastatic colon cancer that has come back or worsened after standard treatment. It may help shrink tumors and slow disease growth after later-line therapy options.
Hear when a new Colo-rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.